Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced it will present clinical data from its Phase 1/2a trial of EVX-02 at the 2023 American Association for Cancer Research Annual Meeting from April 14-19 in Orlando, Florida. The personalized DNA vaccine, designed to improve melanoma treatment, reportedly induces specific T-cell immune response in patients with resected melanoma. CEO Pér Norlen highlighted the potential of their AI platform, PIONEER, in developing innovative cancer immunotherapies. The presentation is scheduled for April 18, 2023, in the poster session.

Positive

• Presentation of Phase 1/2a trial data for EVX-02 indicating well-tolerated and immune-responsive vaccine.
• CEO highlights potential of AI-powered immunotherapies to improve cancer treatment.

Negative

• None.

COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

Pér Norlen, CEO at Evaxion, said: “Our unique AI platform PIONEER has allowed the development of personalized cancer immunotherapies that have the potential to improve the treatment of melanoma as well as of other cancers. We look forward to sharing the clinical phase 1/2a data of our personalized DNA vaccine EVX-02 with the oncology community during the 2023 AACR meeting.”

Title: A personalized neoantigen vaccine is well tolerated and induces specific T-cell immune response in patients with resected melanoma
Abstract #: 23-LB-9549-AACR
Session: Immune response to therapies
Location: Poster section 35
Time: Tuesday, April 18, 2023 9:00 AM - 12:30 PM

About Evaxion
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of product candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, with 70 employees and is listed on the Nasdaq New York stock exchange. For more information, please visit: www.evaxion-biotech.com.

For more information
Per Norlén, CEO
Evaxion Biotech A/S

via:
Katrine Hertz Mortensen
VP, Communications and Public Relations
khm@evaxion-biotech.com
+45 3010 0203

Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.

FAQ

What is the purpose of the EVX-02 trial?

The EVX-02 trial aims to evaluate the safety and efficacy of a personalized DNA vaccine in patients with resected melanoma.

When will the Phase 1/2a trial results for EVX-02 be presented?

The results will be presented on April 18, 2023, at the 2023 AACR Annual Meeting.

What are the expected outcomes of the EVX-02 trial?

The trial seeks to demonstrate that EVX-02 induces a specific T-cell immune response in melanoma patients.

What potential market impact could the trial results have for EVAX?

Positive results could enhance EVAX's reputation in immunotherapy and lead to increased market interest in their AI-powered product pipeline.